ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

AMITIZA
Colorectal disorders
Constipation and bowel cleansers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

AMITIZA Rx

Generic Name and Formulations:
Lubiprostone 8mcg, 24mcg; caps.

Company:
Sucampo and Takeda

Therapeutic Use:

Indications for AMITIZA:

Irritable bowel syndrome with constipation (IBS–C) in women.

Adult:

Swallow whole. Take with food and water. ≥18yrs: 8mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): initially 8mcg once daily; if tolerated and inadequate response, may escalate to full dose; monitor.

Children:

<18yrs: not established.

Contraindications:

Known or suspected mechanical GI obstruction.

Warnings/Precautions:

Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Hepatic impairment. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers; monitor infants for diarrhea.

Interactions:

Possibly antagonized by diphenylheptane opioids (eg, methadone). Increased risk of syncope/hypotension with antihypertensives.

Pharmacological Class:

GI motility enhancer (chloride channel activator).

Adverse Reactions:

Nausea, diarrhea (discontinue if severe), abdominal pain; syncope, hypotension, dyspnea.

Elimination:

Renal (primary), fecal.

Generic Availability:

NO

How Supplied:

8mcg—60; 24mcg—60, 100

Indications for AMITIZA:

Chronic idiopathic constipation. Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation.

Limitations Of use:

Effectiveness in the treatment of OIC in patients taking diphenylheptane opioids (eg, methadone) has not been established.

Adult:

Swallow whole. Take with food and water. 24mcg twice daily. Moderate hepatic impairment (Child-Pugh Class B): initially 16mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): initially 8mcg twice daily. If tolerated and inadequate response, may escalate to full dose; monitor.

Children:

Not established.

Contraindications:

Known or suspected mechanical GI obstruction.

Warnings/Precautions:

Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Hepatic impairment. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers; monitor infants for diarrhea.

Interactions:

Possibly antagonized by diphenylheptane opioids (eg, methadone). Increased risk of syncope/hypotension with antihypertensives.

Pharmacological Class:

GI motility enhancer (chloride channel activator).

Adverse Reactions:

Nausea, diarrhea (discontinue if severe), headache, abdominal pain, abdominal distension, flatulence; syncope, hypotension, dyspnea.

Elimination:

Renal (primary), fecal.

Generic Availability:

NO

How Supplied:

8mcg—60; 24mcg—60, 100

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs